Back to News
Market Impact: 0.3
Veracyte Acquires Convergent Genomics For $150 Mln In Cash
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechTechnology & Innovation
Veracyte acquired Convergent Genomics, adding the UroAmp platform and proprietary urinary tumor-DNA technology to its diagnostics portfolio. The transaction expands Veracyte's molecular diagnostics capabilities in cancer testing, though no financial terms or expected revenue contribution were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
VCYT0.65
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Microsoft's Big Bets on AI Start to Pay Off
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target
- Can Southeast Asia pitch itself as an ‘all-in-one’ chip hub?